[C2] Corporate Exhibitions

[C2-01] Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms

*Taro Saito¹, Arnaud Couzinet², Toshihiro Suzuki², Kei Miyakawa³, Tetsuya Nakatsura² (1. Canon Medical Diagnostics Corporation (Japan), 2. Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center (Japan), 3. Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan))

キーワード：

Cellular immunity、mRNA vaccine、SARS-CoV-2、EAGL assay

閲覧にはパスワードが必要です

ログイン

または